In her first message of a new series about NCATS’ problem-solving approaches, NCATS Director Joni Rutter shares key points about translational science.
Read More

The AMP® Bespoke Gene Therapy Consortium Selects Rare Diseases for Clinical Trial Portfolio

Read about the eight rare diseaes selected for the Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium clinical trial portfolio.

Researchers Build Natural Language Processing Software to Improve Health Care Research

Learn how NCATS awardees use small business funding and CTSA Program grants to commercialize a customizable natural language processing software.

Experts Agree DNA Testing for Treatable Rare Diseases Should Be Available for All Newborns

Read about a study that found 88% of experts surveyed on rare diseases agreed DNA testing to reveal treatable genetic disorders should be available for all infants.

NCATS Scientists Turn Stem Cells Into Neurons to Better Predict Pain Therapies’ Effectiveness

Find out how an innovative process developed by NCATS scientists could help accelerate the search for more effective pain therapies.

New 3-D Models Offer Insights Into the Biology of a Rare Neurological Disease

Discover how NCATS scientists created human cell–based models of a rare disorder, NGLY1 deficiency, to learn more about the disease’s development and biology.

Researchers Create System That Reveals the Location and Gene Activity of Cells in Tumors

Scientists created a system to pair the location of cells in a tumor with their gene activity. The work can help us understand how cancer grows and responds to treatment.

Learn more about these and other staff members >